SVB Leerink Downgrades Moderna (MRNA) to Underperform

Go back to SVB Leerink Downgrades Moderna (MRNA) to Underperform

Moderna (MRNA) changes point to an 'extended period of underperformance' - SVB Securities

February 24, 2023 10:16 AM EST

Moderna (NASDAQ: MRNA) was cut to Underperform from Market Perform by SVB Securities analyst Mani Foroohar on Friday.

Foroohar also lowered the firm's price target on the stock to $93 from $111 following Thursday's reported FY22 results and updated 2023 guidance which "gave a deeper... More